Our assessment of the correlations between serum FGF19, synthesis of BA, cholestasis, and prognosis advances our understanding of the pathophysiology of PBC-AIH OS and allows the potential therapeutic benefits of suppressing hepatic BA synthesis to be evaluated. The gene discussed is FGF19; the disease is autoimmune hepatitis.